Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK NASDAQ:BHST NASDAQ:GNLX NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.23 million shsN/ABHSTBioHarvest Sciences$7.12-0.8%$6.77$4.66▼$7.86$116.91M0.6515,268 shs4,094 shsGNLXGenelux$3.06-0.7%$2.79$1.60▼$5.89$116.68M-0.34172,755 shs149,571 shsPLXProtalix BioTherapeutics$1.43+3.3%$1.59$0.82▼$3.10$113.44M-0.23893,330 shs471,582 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+1.89%-61.87%BHSTBioHarvest Sciences+1.84%+0.56%-0.28%+27.76%+717,999,900.00%GNLXGenelux-8.88%-11.49%+0.65%+19.84%+17.56%PLXProtalix BioTherapeutics-2.82%-6.76%-7.38%-46.92%+18.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos3.3246 of 5 stars3.10.00.04.70.02.51.3BHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AGNLXGenelux1.1999 of 5 stars3.60.00.00.02.60.00.0PLXProtalix BioTherapeutics2.801 of 5 stars3.53.00.00.02.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.25Hold$2.00507.72% UpsideBHSTBioHarvest Sciences 3.00Buy$13.6791.95% UpsideGNLXGenelux 3.20Buy$17.75480.63% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00952.63% UpsideCurrent Analyst Ratings BreakdownLatest ALLK, PLX, BHST, and GNLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ABHSTBioHarvest Sciences$25.19M4.64N/AN/A$0.08 per share89.00GNLXGenelux$10K11,543.23N/AN/A$0.76 per share4.02PLXProtalix BioTherapeutics$59.76M1.90$0.08 per share17.80$0.47 per share3.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)BHSTBioHarvest Sciences-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)GNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.04N/A4.60N/A-21.03%-30.89%-11.74%N/ALatest ALLK, PLX, BHST, and GNLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/AGNLXGenelux-$0.22N/AN/AN/AN/AN/A8/6/2025Q2 2025ALLKAllakos-$0.24N/AN/AN/AN/AN/A5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08BHSTBioHarvest SciencesN/A0.510.30GNLXGeneluxN/A4.674.67PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%BHSTBioHarvest SciencesN/AGNLXGenelux37.33%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%BHSTBioHarvest SciencesN/AGNLXGenelux9.30%PLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableBHSTBioHarvest SciencesN/A16.42 millionN/AN/AGNLXGenelux1037.76 million34.23 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableALLK, PLX, BHST, and GNLX HeadlinesRecent News About These CompaniesPLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...July 10, 2025 | marketwatch.comProtalix BioTherapeutics (NYSE:PLX) Shares Up 3.4% - Still a Buy?July 10, 2025 | marketbeat.comProtalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitutionJune 30, 2025 | proactiveinvestors.comProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | finance.yahoo.comPLX: First Quarter ResultsMay 13, 2025 | msn.comEarnings call transcript: Protalix Q1 2025 results miss forecasts, stock plungesMay 10, 2025 | uk.investing.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 10, 2025 | finanznachrichten.deProtalix BioTherapeutics Q1 Earnings PreviewMay 10, 2025 | msn.com1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings PreviewMay 10, 2025 | benzinga.comProtalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comProtalix eyes Phase II gout trial later this year following solid Q1 revenue growthMay 9, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 9, 2025 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025May 6, 2025 | seekingalpha.comWhy Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%April 15, 2025 | aaii.comAProtalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising PipelineApril 10, 2025 | seekingalpha.comProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025March 24, 2025 | finance.yahoo.comIs Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?March 22, 2025 | msn.comProtalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMIMarch 21, 2025 | proactiveinvestors.comProtalix Stock (PLX) Grabbing Attention with Record Revenue SurgeMarch 20, 2025 | markets.businessinsider.comProtalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLK, PLX, BHST, and GNLX Company DescriptionsAllakos NASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.BioHarvest Sciences NASDAQ:BHST$7.12 -0.06 (-0.84%) As of 03:28 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Genelux NASDAQ:GNLX$3.06 -0.02 (-0.81%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Protalix BioTherapeutics NYSE:PLX$1.42 +0.05 (+3.26%) Closing price 03:58 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
